Skip to main content

Table 1 Patient characteristics

From: Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor

All patients (n) 6
 Male 1
 Female 5
Age (years)
 Average 65
 Range 57–75
EGFR mutation (n)
 Exon 18 G719X 2
 Exon 19 Del E746-A750 1
 Exon 21 L585R 3
Treatment (n)
 Erlotinib 2
 Gefitinib 4